The text starts here.
Understanding Eisai

Which are Eisai's Global Brands?: Four global brands to support sustainable growth

Neurology Area – Fycompa® and BELVIQ®

Two representative products in the Neurology Area are Fycompa®, an in-house developed anti-epileptic agent, and BELVIQ®, an anti-obesity treatment.
Fycompa® was launched in Europe in September 2012 and in the U.S. in January 2014 as an adjunctive treatment for partial-onset seizures with or without secondarily generalized seizures in epilepsy patients aged 12 years and older. Additionally, in June 2015, Eisai received approvals in the U.S. and Europe for an indication expansion regarding the use of Fycompa® as an adjunctive treatment of primary generalized tonic-clonic seizures. In May 2016, Fycompa® was also launched in Japan, and is currently approved in more than 55 countries and territories as an adjunctive treatment of partial-onset seizures and has also been approved in more than 45 countries for the adjunctive therapy of primary generalized tonic-clonic seizures. In July 2017, Eisai obtained approval for monotherapy use in patients with partial-onset seizures in the U.S.
BELVIQ® is an anti-obesity agent launched in the U.S. in June 2013. It is thought to promote weight loss by inducing a feeling of satiety so that patients feel full and eat less by selectively activating serotonin 2C receptors in the brain.

Oncology Area – Lenvima® and Halaven®

Two representative products in the Oncology Area are Lenvima®, an in-house developed selective tyrosine kinase inhibitor with a novel binding mode, and Halaven®, another in-house developed anticancer agent.
Lenvima® was launched successively for the indication of thyroid cancer in the U.S. in February, in Japan in May and in Europe in June. In the U.S., Eisai received approval for an additional indication in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy in May 2016. Halaven® is a synthetic analog of halichondrin B derived from the marine sponge Halichondria okadai that shows an antitumor effect by arresting the cell cycle through inhibition of the growth of microtubules. Halaven® is currently used mainly as a treatment for patients with breast cancer, and was additionally approved for the indication of soft tissue sarcoma in the U.S., Japan and Europe in 2016. Since its launch in the U.S. in 2010, Halaven® has been approved for the indication of breast cancer in more than 60 countries worldwide.

Back
Chocola BB and Nabolin are Eisai's Main Products?
Next
What are the Other Aspects of Eisai?

For more detailed information:
View detailed information Check Eisai glossaryList

Sales of Major Products
Click here for expressions associated with this page
BELVIQ®Open a separeate window
Fycompa®Open a separeate window
Halaven®Open a separeate window
Lenvima®Open a separeate window
Prescription pharmaceuticalsOpen a separeate window

   Understanding Eisai

Related Links